Clorox (NYSE:CLX) Price Target Cut to $129.00 by Analysts at Barclays

Clorox (NYSE:CLX - Free Report) had its price objective decreased by Barclays from $134.00 to $129.00 in a research note published on Wednesday morning, Marketbeat Ratings reports. Barclays currently has an underweight rating on the stock.

A number of other equities research analysts have also recently commented on CLX. Evercore ISI increased their target price on Clorox from $145.00 to $155.00 in a research note on Tuesday, February 4th. Royal Bank of Canada restated a "sector perform" rating and set a $150.00 price objective on shares of Clorox in a research note on Thursday, January 30th. Morgan Stanley dropped their target price on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday. Citigroup reduced their price target on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research report on Monday, April 14th. Finally, JPMorgan Chase & Co. lowered their price objective on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research report on Tuesday. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $151.23.

Clorox Stock Down 2.2 %

Shares of Clorox stock traded down $3.02 during trading on Wednesday, hitting $134.79. The company's stock had a trading volume of 1,934,590 shares, compared to its average volume of 1,307,001. Clorox has a 52 week low of $127.60 and a 52 week high of $171.37. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94. The company has a fifty day simple moving average of $142.37 and a two-hundred day simple moving average of $154.10. The company has a market capitalization of $16.60 billion, a PE ratio of 36.83, a P/E/G ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. Clorox's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.71 earnings per share. Equities research analysts predict that Clorox will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 9th. Stockholders of record on Wednesday, April 23rd were given a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a dividend yield of 3.62%. The ex-dividend date of this dividend was Wednesday, April 23rd. Clorox's payout ratio is currently 87.61%.

Insider Transactions at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of Clorox stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $546,280. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.57% of the company's stock.

Institutional Investors Weigh In On Clorox

Hedge funds have recently modified their holdings of the business. Brooklyn Investment Group raised its stake in shares of Clorox by 163.8% in the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company's stock worth $25,000 after buying an additional 95 shares during the period. Redwood Park Advisors LLC bought a new stake in Clorox during the 4th quarter worth approximately $26,000. Millstone Evans Group LLC bought a new stake in Clorox during the 4th quarter worth approximately $31,000. Wood Tarver Financial Group LLC purchased a new position in Clorox during the fourth quarter valued at approximately $31,000. Finally, Asset Planning Inc bought a new position in shares of Clorox in the fourth quarter worth approximately $32,000. Institutional investors own 78.53% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.